OncoCyte (NASDAQ:OCX – Get Free Report) and Danaher (NYSE:DHR – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.
Insider & Institutional Ownership
55.3% of OncoCyte shares are owned by institutional investors. Comparatively, 79.1% of Danaher shares are owned by institutional investors. 1.9% of OncoCyte shares are owned by insiders. Comparatively, 11.1% of Danaher shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares OncoCyte and Danaher’s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
OncoCyte | $1.50 million | 14.07 | -$27.78 million | N/A | N/A |
Danaher | $23.89 billion | 7.33 | $4.76 billion | $6.39 | 36.99 |
Profitability
This table compares OncoCyte and Danaher’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
OncoCyte | -3,923.58% | -77.26% | -33.66% |
Danaher | 17.26% | 12.25% | 7.43% |
Risk & Volatility
OncoCyte has a beta of 0.8, meaning that its stock price is 20% less volatile than the S&P 500. Comparatively, Danaher has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and recommmendations for OncoCyte and Danaher, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
OncoCyte | 0 | 2 | 2 | 0 | 2.50 |
Danaher | 0 | 5 | 10 | 0 | 2.67 |
OncoCyte currently has a consensus price target of $3.90, indicating a potential upside of 52.34%. Danaher has a consensus price target of $268.27, indicating a potential upside of 13.49%. Given OncoCyte’s higher possible upside, equities research analysts clearly believe OncoCyte is more favorable than Danaher.
Summary
Danaher beats OncoCyte on 10 of the 12 factors compared between the two stocks.
About OncoCyte
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.